文档介绍：托伐普坦联合小剂量多巴***治疗顽固性心衰的临床分析
[摘要] 目的 分析托伐普坦聯合小剂量多巴***应用在顽固性心衰患者治疗中的临床疗效。 方法 方便选取该院收治的123例患者进行研究,患者的入选时间范围在2015年8月—±) L. The body mass decreased (±) kg before and after treatment, and the cardiac ejection fraction increased (±)%. Among them, the cardiac ejection fraction was compared with group A and There was no significant difference between the two groups (t= 9、 4,P>). The data of weight loss and daily mean before and after treatment were statistically significant compared with group A and group B (t= 3、 3、 5、 4,). However, it was higher than group A (t= 2, 0,); group A dyspnea score (±)points, general condition (±)points, and various data with group A, B Group comparisons were significantly lower, and the data were statistically significant (t= 7、 4、 7、 5,P<); the NT-PROBNP level in group C was (2 ±1 ) g/L. The difference between the two groups was statistically significant (t= 4、 8,P<); the cTnI of the C group was (±) μg/L, and the hs-CRP was (±) μg/L. There was no statistically significant difference between group A and group B (t= 9、 5、 7、 4,P<). Conclusion Tolvaptan combined with low-dose dopamine in the treatment of refractory heart failure has obvious effects, can improve the syste